Alnylam Historical Income Statement
| ALNY Stock | USD 145.32 1.40 0.95% |
Historical analysis of Alnylam Pharmaceuticals income statement accounts such as Interest Expense of 127.3 M, Other Operating Expenses of 2.2 B or Research Development of 1.1 B can show how well Alnylam Pharmaceuticals performed in making a profits. Evaluating Alnylam Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Alnylam Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Alnylam Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Alnylam Pharmaceuticals is a good buy for the upcoming year.
Alnylam |
About Alnylam Income Statement Analysis
Alnylam Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Alnylam Pharmaceuticals shareholders. The income statement also shows Alnylam investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Alnylam Pharmaceuticals Income Statement Chart
Alnylam Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Alnylam's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Alnylam Pharmaceuticals revenue and expense. Alnylam Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Alnylam Pharmaceuticals' Tax Provision is fairly stable compared to the past year. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Alnylam Pharmaceuticals. It is also known as Alnylam Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Alnylam Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Tax Provision is fairly stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 704.1M | 868.6M | 1.5B | 1.6B | Total Revenue | 844.3M | 1.0B | 1.8B | 1.9B |
Alnylam Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Alnylam Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alnylam Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 54.4M | 57.3M | (471K) | (109.4M) | 54.1M | 56.8M | |
| Interest Expense | 108.5M | 84.5M | 143.0M | 156.0M | 121.2M | 127.3M | |
| Other Operating Expenses | 1.2B | 1.3B | 1.6B | 1.8B | 2.1B | 2.2B | |
| Operating Income | (939.4M) | (828.4M) | (708.7M) | (785.1M) | (282.2M) | (296.3M) | |
| Ebit | (939.4M) | (828.4M) | (708.7M) | (785.1M) | (282.2M) | (296.3M) | |
| Research Development | 655.1M | 654.8M | 792.2M | 883.0M | 1.0B | 1.1B | |
| Ebitda | (885.1M) | (771.1M) | (709.1M) | (894.4M) | (228.1M) | (239.5M) | |
| Total Operating Expenses | 1.1B | 1.2B | 1.4B | 1.7B | 1.8B | 1.9B | |
| Net Income | (886.1M) | (858.3M) | (852.8M) | (1.1B) | (440.2M) | (462.3M) | |
| Income Tax Expense | 863K | 2.7M | 680K | 4.2M | 6.7M | 7.1M | |
| Selling General Administrative | 479.0M | 588.4M | 620.6M | 770.7M | 795.6M | 835.4M | |
| Total Revenue | 219.8M | 492.9M | 844.3M | 1.0B | 1.8B | 1.9B | |
| Gross Profit | 194.7M | 414.8M | 704.1M | 868.6M | 1.5B | 1.6B | |
| Cost Of Revenue | 25.1M | 78.1M | 140.1M | 168.8M | 310.4M | 178.7M | |
| Income Before Tax | (885.3M) | (855.6M) | (852.1M) | (1.1B) | (433.5M) | (455.2M) | |
| Total Other Income Expense Net | 54.2M | (27.2M) | (143.5M) | (341.9M) | (151.3M) | (143.8M) | |
| Net Income From Continuing Ops | (886.1M) | (858.3M) | (852.8M) | (1.1B) | (440.2M) | (462.3M) | |
| Non Operating Income Net Other | 54.2M | 57.3M | (471K) | (186.0M) | (167.4M) | (159.0M) | |
| Net Income Applicable To Common Shares | (886.1M) | (858.3M) | (852.8M) | (1.1B) | (1.0B) | (967.1M) | |
| Interest Income | 33.4M | 11.8M | 1.6M | 24.8M | 95.6M | 100.3M | |
| Tax Provision | 863K | 2.7M | 680K | 4.2M | 6.7M | 7.1M | |
| Net Interest Income | 33.4M | (72.7M) | (141.4M) | (131.2M) | (25.7M) | (26.9M) | |
| Reconciled Depreciation | 54.4M | 74.4M | 89.7M | 85.6M | 97.0M | 66.1M |
Alnylam Pharmaceuticals Investors Sentiment
The influence of Alnylam Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Alnylam. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Alnylam Pharmaceuticals' public news can be used to forecast risks associated with an investment in Alnylam. The trend in average sentiment can be used to explain how an investor holding Alnylam can time the market purely based on public headlines and social activities around Alnylam Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Alnylam Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Alnylam Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Alnylam Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Alnylam Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alnylam Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alnylam Pharmaceuticals' short interest history, or implied volatility extrapolated from Alnylam Pharmaceuticals options trading.
Pair Trading with Alnylam Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Alnylam Stock
| 0.78 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.77 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.73 | MRSN | Mersana Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.64 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.63 | INZY | Inozyme PharmaInc Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.
The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.53) | Revenue Per Share 14.637 | Quarterly Revenue Growth 0.312 | Return On Assets (0.05) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.